nterim data from the first-in-human clinical study of TERN-201 demonstrate that single, oral administrations of TERN-201 were well tolerated with no significant safety findings or adverse events observed that led to discontinuation.
Each dose level studied resulted in decreases from baseline in plasma SSAO activity that were maintained up to one week after single dose administrations of TERN-201.
Based on these results, the study has progressed to the multiple-dose phase.
The first-in-human trial of TERN-201 is a multiple phase, single- and multiple-ascending dose study in healthy human participants. In the first phase, study volunteers receive a single dose of TERN-201 or placebo in ascending dose cohorts.
In the second phase of the study, healthy participants receive repeat doses of TERN-201 or placebo, also in ascending dose cohorts.
The primary endpoint for each phase of the trial is safety and tolerability. Secondary endpoints include pharmacokinetics and pharmacodynamic biomarker assessments of SSAO target engagement.
TERN-201 was initially discovered and developed by Eli Lilly and company. Terns signed a global, exclusive agreement with Eli Lilly in 2018 to develop, manufacture, and commercialise TERN-201 for the treatment of NASH.
At The International Liver Congress 2019 in Vienna, Terns presented preclinical data demonstrating that TERN-201 improves the NAFLD Activity Score and fibrosis in rodent models of NASH.
Terns Pharmaceuticals is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer.
Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis and cancer, across multiple modalities.
Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval